| Identification | Back Directory | [Name]
[1,2,4]Triazolo[4,3-a]quinoxaline, 8-[5-(difluoromethyl)-3-pyridinyl]-1-(2,3,6,7-tetrahydro-4-oxepinyl)- | [CAS]
2763602-59-9 | [Synonyms]
[1,2,4]Triazolo[4,3-a]quinoxaline, 8-[5-(difluoromethyl)-3-pyridinyl]-1-(2,3,6,7-tetrahydro-4-oxepinyl)- | [Molecular Formula]
C21H17F2N5O | [MOL File]
2763602-59-9.mol | [Molecular Weight]
393.4 |
| Hazard Information | Back Directory | [Uses]
BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (IC50=81 nM). BAY-8400 can be used for the research of cancer[1]. | [in vivo]
BAY-8400 (150 mg/kg; p.o.) increases the antitumor efficacy. BAY-8400 shows useful aqueous solubility and oral bioavailability across species[1]. | [References]
[1] Berger M, et al. BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies [published online ahead of print, 2021 Aug 24]. J Med Chem. 2021;10.1021/acs.jmedchem.1c00762. DOI:10.1021/acs.jmedchem.1c00762 |
|
|